TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: VTE Exclusion
Endpoint domain: Adverse events/effects
Primary endpoint: toxicity of sequential PDT and chemoradiation
Endpoint domain: Adverse events/effects
Primary endpoint: 3 year recurrence-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Operational feasibility
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Best Overall Response Rate (BORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of Adverse Events/Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Superior Sagittal Sinus Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Torcula Sinus Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Dominant Transverse Sinus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Dominant Transverse-Sigmoid Sinus Junction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Dominant Sigmoid Sinus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Dominant Internal Jugular Vein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Absolute Change in Dual Task Cost to Gait Speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute Change in Dual Task Cost to Standing Postural Sway Speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metabolomics readout
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in VLDL-apoB100 Production Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Extent of contrast medium passage through the Eustachian tube
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Plaque Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cure or relapse within 36 months
Endpoint domain: Mortality/survival
Primary endpoint: Body composition measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glycemic control - HbA1< 7%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Gastrointestinal output
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Toxicity Profile
Endpoint domain: Adverse events/effects
Primary endpoint: Seattle Angina Questionnaire Score Change
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Major structural malformations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in intestinal bacterial microflora
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage of Patients in Major Molecular Response (MMR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: safety/tolerability of dose combinations
Endpoint domain: Adverse events/effects
Primary endpoint: pharmacokinetics of combination therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in vessel diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Bone-ridge width
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with Immune-Mediated Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Early detection of hepatocellular carcinoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Histologic characteristics of malignant peripheral nerve sheath tumor (MPNST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Immunohistochemical characteristics of malignant peripheral nerve sheath tumor (MPNST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Molecular characteristics of malignant peripheral nerve sheath tumor (MPNST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiographic characteristics of malignant peripheral nerve sheath tumor (MPNST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment given to patients with malignant peripheral nerve sheath tumor (MPNST)
Endpoint domain: Adverse events/effects
Primary endpoint: Lipoprotein composition differences-glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lipoprotein composition differences-insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lipoprotein composition differences-c-reactive protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Lipoprotein composition differences-lipid concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lipoprotein composition differences-chemistry panel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of the optimal regimen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to complete medical oncology review
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in PAS-Long-term-potentiation (PAS-LTP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in N-Back Performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Numeric pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with approved injury insurance claims
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of Patients With Normal Body Temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total volume smoke inhaled
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early Post-operative Intraocular Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Pathogen dynamics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in Motor Function Measure-32 (MFM-32)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Target Tumor Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of Participants Who Are Seropositive by cLIA to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58: Month 7
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cLIA GMTs for HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 in Participants 9 to 19 Years of Age: Month 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Who Are Seropositive by cLIA to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58: Month 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of LVEF assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: SST-12
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Maximum Tolerated Dose (MTD) of Olaparib and Temozolomide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Response Rate for Olaparib and Temozolomide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of the derotation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Adherence as measured by number of minutes
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change in Conner's Continuous Performance Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Adherence as measured by number of sessions
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Hypersalivation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Optimal Mean Blood Pressure Value at 24 Hours of Life
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reliability of anchorage for sound processor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percent of patients achieving triglycerides <200 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Study completion
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Physical Activity (PA) Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ECOG Performance Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: one-year recurrence
Endpoint domain: Mortality/survival
Primary endpoint: nerve shear wave velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Peak Serum Concentration (CMax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Concentration Immediately before Next Dose (Ctrough)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Serum Concentration-Time Curve from Zero to Infinity (AUC0-inf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Pathologic Complete Response (pCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Serum Non-HDL Cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: onset of hunger
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: onset of bowel movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: onset of flatus passing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: onset of defecation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Presence of mRNA in circulating tumor cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: doctor-confirmed dilated eye examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: thermic effect of food
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Glucose production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: GCF MCP-1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of neurocognitive function
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Percentage of ulcer complete healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-14
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C312
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Invasive Disease-free Survival
Endpoint domain: Mortality/survival
Primary endpoint: CD4+ T cell count greater than 200
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Blood cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Energy Intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Symptoms of Depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Symptoms of Anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Adverse event frequency and severity
Endpoint domain: Adverse events/effects
Primary endpoint: Emergency department utilization rates for patients post-discharge
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Levels of oxidant injury in cerebrospinal fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of Participants Experiencing Any Grade 2 or Higher Clinical Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of Participants Who Discontinue Receiving Injections Due to Intolerability
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of Participants Who Complete All Scheduled Injections
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Mean change from baseline in student report on aggression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean change from baseline in teacher report on students' aggression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean change from baseline in student aggression as measured by Office Discipline Referrals
Endpoint domain: Life impact
Endpoint subdomain: Behavioral functioning
Primary endpoint: Initial Cervical Dilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Occurrence of treatment related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Disease Re-occurrence Following FMT
Endpoint domain: Mortality/survival
Primary endpoint: No Result Percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Participants' comprehension of an intervention tool
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Intergenerational transfer of diet-related behaviors
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Area under the capillary blood concentration-time curve (AUC) of caffeine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the capillary blood concentration-time curve (AUC) of dextromethorphan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the capillary blood concentration-time curve (AUC) of flurbiprofen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the capillary blood concentration-time curve (AUC) of midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the capillary blood concentration-time curve (AUC) of omeprazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bleb height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bleb extent and vascularity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal participant tolerance of bone marrow harvest
Endpoint domain: Adverse events/effects
Primary endpoint: Safety of in utero hematopoietic stem cell transplantation
Endpoint domain: Adverse events/effects
Primary endpoint: Presence of autoantibodies to IFNy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Plasma concentrations of Certolizumab pegol (CZP) at Week 16
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma anti-CZP antibody titers at Week 16
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentrations of CZP at Week 52
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma anti-CZP antibody titers at Week 52
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of glucose homeostasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Assessment of mean glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area Under the Plasma Concentration Versus Time Curve from Time Zero to the Time of the Last Measurable Concentration (AUC0-last)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Plasma Concentration Observed (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apparent Terminal Elimination Half-life (t1/2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thyroid function tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Thyroid morphology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients With Dose Limiting Toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: proportion of patients with appropriate management
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of post-biopsy infection
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Asparaginase-Related Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Induction and Post-Induction Nadir Serum Asparaginase Activity Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall-response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Patients With Composite Event (BPAR, Graft Loss or Death)
Endpoint domain: Mortality/survival
Primary endpoint: Rapid progression of kidney function loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: social-emotional health
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: behavioral health
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Action Research Arm Test Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: perceived Pain
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Treatment adherence as measured by pill count
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Duration and intensity of brain retraction pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Complete response rate in the carcinoma in situ (CIS) subpopulation
Endpoint domain: Mortality/survival
Primary endpoint: Event-free survival at 18 months
Endpoint domain: Mortality/survival
Primary endpoint: Mean change in FEV1 (mL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Perihematomal Edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: World Health Organization Disability Assessment Schedule
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Brief Pain Inventory
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Adverse events as graded by CTCAE v5.0
Endpoint domain: Adverse events/effects
Primary endpoint: Immunogenicity measured by interferon-γ secreting T lymphocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Immunogenicity measured by T-cell activation and cytolytic cell phenotype
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Social & relational factors
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Late Grade ≥ 3 Gastrointestinal Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Late Grade ≥ 3 Genitourinary Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Functional outcomes assessment
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: rate of increase in alveolar bone height
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Diagnostic accuracy of capsule endoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Participants With Dose-Limiting Toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) by Severity
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Clinically Significant Laboratory Abnormalities in Hematology, Chemistry, and Urinalysis
Endpoint domain: Adverse events/effects
Primary endpoint: Toxicity events
Endpoint domain: Adverse events/effects
Primary endpoint: P1 amplitude elicited in the dot-probe task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Bucco-lingual bone width
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in Corono-apical bone height
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Total bone volume change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Vascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Composite rate of all-cause mortality
Endpoint domain: Mortality/survival
Primary endpoint: Composite rate of all stroke
Endpoint domain: Mortality/survival
Primary endpoint: Composite rate of rehospitalization
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Altered Heparin Responsiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Adherence to hearing aids
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of nodules/lesions identified by surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of nodules/lesions identified by histology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Daily Symptom Rating Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status